Main Article Content
Background and Aim: Cirrhotic patients have lower response rates to DAAs with increased frequency of adverse events. This study aims to evaluate the value of HCVcAg as an early predictor of SVR to DAAs in cirrhotic patients to justify the treatment and avoid side effects.
Patients and Methods: This prospective cohort study was conducted on 85 treatment-naive HCV cirrhotic patients who had fulfilled the inclusion and exclusion criteria of the National Treatment Protocol of chronic HCV infection. HCVcAg detection was done on 10th day of treatment. Predictivity of HCVcAg for SVR was assessed in terms of specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV) and accuracy rates. ROC curve was conducted to assess predictivity of HCVcAg as well.
Results: SVR12 was (91.76%). HCVcAg was negative in 79 patients; 78 of them achieved SVR, while it was positive in 6 patients; all of whom did not achieve SVR. HCVcAg had sensitivity, specificity, PPV, NPV and accuracy rates of 100%, 98.73%, 85.71%, 100% and 98.82% respectively in prediction of SVR. With AUC of 0.929. There was a positive strong significant correlation between HCVcAg and SVR12 (r = 0.898, P = 0.015).
Conclusion: HCVcAg is a sensitive, specific, accurate, easily available, and affordable on- treatment predictor of SVR in cirrhotic patients with chronic HCV with possible future treatment regimen modification to improve efficacy and tolerability in difficult to treat cirrhotic patients.
Sheridan DA, Neely RDG and Bassendine MF. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clinics research in hepatologygastroenterology. 2013;37:10-6.
Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593-601.
Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015;61:790-801.
Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G, et al. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Sci Rep. 2017.;7,:16017
European Association for the Study of the Liver (EASL). EASL Recommendations on Treatment of Hepatitis C. J Hepatol. 2018. Available:https://doi.org/10.1016/j.jhep.2018.03.026.
AASLD-IDSA HCV Guidance Panela. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases. 2018;67:1477-1492.
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649-659
Takahashi K, Okamoto H, Kishimoto S, Munekata E, Tachibana K, Akahane Y et al. Demonstration of a hepatitis C virus-specific antigen predicted from the putativecore gene in the circulation of infected hosts. J Gen Virol.1992;73:667–72.
Chang C, Hung CH, Wang JH, Lu SN. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci.2018;34:684–8.
Leary T, Gutierrez R, Muerhoff A, Birkenmeyer L, Desai S, Dawson G.A chemiluminescent, magnetic particle‐based immunoassay for the detection of hepatitis C virus core antigen in human serum or plasma. Journal of medical virology. 2006;78:1436-1440.
Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K. et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol. 2009;46: 210-5.
Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology. 2006;43:S207-20
Tillmann HL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. World journal of gastroenterology: WJG. 2014;20:6701.
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127-35.
Sulkowski M, Gardiner D, Rodriguez-Torres M, Reddy K, Hassanein T, Jacobson I et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
Fontaine H, Hezode C, Zoulim F, Samuel D, Bourliere M, Haour G, et al. Efficacy of the oral sofosbuvir based combinations in HCV genotype 4monoinfected patients from the French observational cohort ANRS CO22 Hepather. Abstract LP28 presented at: 50th Annual Meeting of European Association for the Study of the Liver, April 22–26, Vienna, Austria;2015.
Fujino T, Nakamuta M, Aoyagi Y, Fukuizumi K, Takemoto R, Yoshimoto T, et al. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by pegylated interferon plus ribavirin combination therapy. Journal of digestive diseases. 2009;10:21-5.
Feng B, Yang RF, Xie Q, Shang J, Kong FY, Zhang HY, et al. Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. BMC gastroenterology. 2014;14:47.
Nguyen LT, Gray E, O'Leary A, Carr M, De Gascun CF and Irish Hepatitis C Outcomes Research Network. The role of hepatitis C virus core antigen testing in the era of direct acting antiviral therapies: what we can learn from the protease inhibitors. PLoS One. 2016;11:e0163900.
Lamoury FMJ, Soker A, Martinez D, Hajarizadeh B, Cunningham EB, Cunningham P, et al. Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. J Clin Virol. 2017;92:32-38.
Lucejko M, Flisiak R. Quantitative measurement of HCV core antigen for management of interferon-free therapy in HCV-infected patients. Antivir ther. 2018; 23:149-156.
Van Tilborg M, Al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, et al. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. Lancet Gastroenterol Hepatol. 2018;3:856-864.